Structures by: Oswald I. D.
Total: 194
Paracetamol hemi(N-Methylmorpholine)
2[C8H9NO2][C5H11NO]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=10.5749(8)Å b=11.0221(8)Å c=9.3894(7)Å
α=90.00° β=101.145(2)° γ=90.00°
Paracetamol-bipyridine
[C8H9NO2][C10H8N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=11.2906(10)Å b=24.103(2)Å c=11.5526(10)Å
α=90.00° β=96.1484(16)° γ=90.00°
2[C8H9NO2][C4H9NO]
2[C8H9NO2][C4H9NO]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=7.2791(9)Å b=14.6277(18)Å c=18.303(2)Å
α=90.00° β=90.00° γ=90.00°
Paracetamol hemi-dioxane
2[C8H9O2N],[C4H8O2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=12.421(5)Å b=12.056(4)Å c=13.396(3)Å
α=90.00° β=91.51(3)° γ=90.00°
Glycolide
C4H4O4
Acta Crystallographica Section B (2017) 73, 6 1151-1157
a=5.1174(4)Å b=7.3666(4)Å c=11.7174(10)Å
α=90° β=90° γ=90°
Glycolide
C4H4O4
Acta Crystallographica Section B (2017) 73, 6 1151-1157
a=4.8571(4)Å b=7.1033(5)Å c=11.4462(10)Å
α=90° β=90° γ=90°
Glycolide
C4H4O4
Acta Crystallographica Section B (2017) 73, 6 1151-1157
a=4.9209(4)Å b=7.1818(5)Å c=11.5243(10)Å
α=90° β=90° γ=90°
Glycolide
C4H4O4
Acta Crystallographica Section B (2017) 73, 6 1151-1157
a=4.7757(4)Å b=6.9930(5)Å c=11.3384(10)Å
α=90° β=90° γ=90°
Glycolide
C4H4O4
Acta Crystallographica Section B (2017) 73, 6 1151-1157
a=4.7321(4)Å b=6.9298(5)Å c=11.2798(11)Å
α=90° β=90° γ=90°
C4H10N2
C4H10N2
Acta Crystallographica Section B (2004) 60, 2 219-227
a=6.0079(15)Å b=5.1920(13)Å c=8.407(2)Å
α=90° β=108.254(4)° γ=90°
C4H9N1O1
C4H9N1O1
Acta Crystallographica Section B (2004) 60, 2 219-227
a=5.2311(5)Å b=8.2292(7)Å c=11.1370(10)Å
α=90° β=90° γ=90°
C5H11N1
C5H11N1
Acta Crystallographica Section B (2004) 60, 2 219-227
a=8.6989(7)Å b=5.2642(4)Å c=12.0097(10)Å
α=90° β=96.8000(10)° γ=90°
Amoxapine acetate acetic acid monosolvate cyclohexane hemisolvate
C17H17ClN3O,C2H3O2,C2H4O2,0.5(C6H12)
Acta Crystallographica Section E (2015) 71, 2 139-141
a=21.0726(12)Å b=6.0393(3)Å c=18.6087(10)Å
α=90.00° β=92.096(2)° γ=90.00°
Paracetamol--morpholine (1/2.5)
C8H9NO2,2.5C4H9NO
Acta Crystallographica Section E (2002) 58, 11 o1290-o1292
a=8.710(4)Å b=9.920(5)Å c=12.385(5)Å
α=102.35(3)° β=108.33(2)° γ=96.68(3)°
C11H16NO2,Cl
C11H16NO2,Cl
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2015) 71, 1
a=9.4272(2)Å b=7.0774(2)Å c=18.2519(4)Å
α=90° β=90° γ=90°
C11H16NO2,Cl
C11H16NO2,Cl
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2015) 71, 1
a=9.1478(3)Å b=6.9826(3)Å c=17.6799(4)Å
α=90° β=90° γ=90°
C11H16NO2,Cl
C11H16NO2,Cl
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2015) 71, 1
a=8.8661(5)Å b=6.9379(4)Å c=17.120(3)Å
α=90° β=90° γ=90°
C11H16NO2,Cl
C11H16NO2,Cl
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2015) 71, 1
a=8.4895(2)Å b=6.8759(2)Å c=16.6225(14)Å
α=90° β=90° γ=90°
C11H16NO2,Cl
C11H16NO2,Cl
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2015) 71, 1
a=8.4043(2)Å b=6.8578(2)Å c=16.5271(12)Å
α=90° β=90° γ=90°
C11H16NO2,Cl
C11H16NO2,Cl
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2015) 71, 1
a=8.3242(4)Å b=6.8403(3)Å c=16.447(2)Å
α=90° β=90° γ=90°
C11H16NO2,Cl
C11H16NO2,Cl
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2015) 71, 1
a=8.3325(8)Å b=6.814(2)Å c=16.4416(16)Å
α=90° β=90° γ=90°
Loxapine succinate monohydrate
2(C18H19ClN3O),C4H4O42,C4H6O4,2(H2O)
Acta Crystallographica Section C (2013) 69, 11 1273-1278
a=9.4171(6)Å b=9.7604(7)Å c=13.7949(9)Å
α=74.708(2)° β=86.102(2)° γ=65.518(2)°
Loxapine succinate
C18H19ClN3O,C4H5O4
Acta Crystallographica Section C (2013) 69, 11 1273-1278
a=36.1824(5)Å b=7.08622(14)Å c=18.7690(2)Å
α=90° β=113.8402(10)° γ=90°
TGF beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=19.4305(17)Å b=11.3245(11)Å c=9.1511(9)Å
α=90° β=95.302(5)° γ=90°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.2116(11)Å b=11.5104(14)Å c=11.8746(18)Å
α=102.001(10)° β=105.368(11)° γ=102.349(9)°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=7.7119(14)Å b=8.9111(17)Å c=14.617(2)Å
α=81.906(13)° β=78.799(14)° γ=75.258(15)°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=10.7270(3)Å b=14.4711(5)Å c=12.7050(4)Å
α=90° β=107.1120(17)° γ=90°
TGF beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.134(2)Å b=12.620(4)Å c=18.059(3)Å
α=86.707(19)° β=100.094(15)° γ=83.303(19)°
TGF Beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.5537(2)Å b=11.3718(4)Å c=11.5674(5)Å
α=65.784(3)° β=105.495(3)° γ=77.315(2)°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=18.9981(11)Å b=9.8532(6)Å c=21.8829(13)Å
α=90° β=113.219(3)° γ=90°
TGF beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=11.3011(3)Å b=20.8473(5)Å c=8.10637(17)Å
α=90° β=98.879(2)° γ=90°
C22H19N5O
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=27.938(4)Å b=8.0817(7)Å c=22.004(3)Å
α=90° β=133.55(3)° γ=90°
4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=27.654(13)Å b=8.108(8)Å c=21.934(11)Å
α=90° β=133.41(8)° γ=90°
C22H19N5O,H2O
C22H19N5O,H2O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=9.0505(7)Å b=11.3624(9)Å c=19.1323(16)Å
α=90° β=94.954(3)° γ=90°
C22H19N5OCH4O
C22H19N5OCH4O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.0458(4)Å b=22.6024(10)Å c=11.2097(5)Å
α=90° β=106.274(2)° γ=90°
TGF Beta
C22H19N5OC2H6O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.0820(4)Å b=9.2580(4)Å c=15.5250(7)Å
α=73.338(2)° β=89.974(2)° γ=84.594(2)°
TGF Beta
C22H19N5OC3H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=7.7720(11)Å b=11.8319(18)Å c=12.8267(17)Å
α=89.030(9)° β=74.293(8)° γ=82.225(10)°
TGF Beta
C22H19N5OC5H12O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.0879(6)Å b=12.3578(9)Å c=12.8909(9)Å
α=85.722(3)° β=77.875(3)° γ=74.707(3)°
TGF beta
C22H19N5OC4H10O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.1676(2)Å b=11.9112(3)Å c=12.7014(3)Å
α=89.4745(11)° β=81.2360(14)° γ=75.9211(11)°
TGF Beta
C22H19N5O,2(C4H8O2)
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=10.6011(8)Å b=11.6654(9)Å c=12.5667(9)Å
α=69.035(3)° β=86.603(2)° γ=81.573(2)°
TGF beta
C22H19N5O,0.5(C4H8O2),H2O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=7.7332(3)Å b=11.4956(4)Å c=12.1986(4)Å
α=85.299(2)° β=84.505(2)° γ=85.518(2)°
TGF Beta
C22H19N5O,C4H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.3929(7)Å b=11.7452(9)Å c=12.0347(10)Å
α=92.483(3)° β=106.415(4)° γ=97.071(4)°
TGF beta
C22H19N5O,CH2Cl2
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.4961(8)Å b=10.3766(10)Å c=12.7043(12)Å
α=103.239(5)° β=91.904(5)° γ=94.505(5)°
C22H19N5O,C4H10O
C22H19N5O,C4H10O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.1840(8)Å b=12.0219(12)Å c=12.6533(12)Å
α=89.543(6)° β=81.238(6)° γ=75.349(6)°
C22H19N5O,C2H6O
C22H19N5O,C2H6O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.1100(4)Å b=11.6569(6)Å c=12.7599(6)Å
α=90.026(4)° β=99.248(4)° γ=101.238(4)°
C22H19N5O,C2H4O2
C22H19N5O,C2H4O2
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=9.5331(11)Å b=10.9792(13)Å c=11.6291(17)Å
α=66.668(12)° β=65.944(8)° γ=78.915(9)°
C22H19N5OC3H8O
C22H19N5OC3H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.0480(8)Å b=11.4825(13)Å c=12.8727(13)Å
α=89.280(7)° β=80.416(7)° γ=79.313(7)°
TGF beta
C22H19N5O,C5H10O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.5823(11)Å b=11.0257(18)Å c=12.7778(16)Å
α=101.925(12)° β=92.429(11)° γ=97.579(12)°
TGF beta
C22H19N5OC4H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=12.1495(14)Å b=8.4511(9)Å c=20.111(2)Å
α=90° β=93.551(7)° γ=90°
TGF beta
C22H19N5O,C5H9NO
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=9.9660(6)Å b=33.730(2)Å c=7.3404(5)Å
α=90° β=106.892(2)° γ=90°
C22H19N5O4Pt1S2
C22H19N5O4Pt1S2
Inorganic Chemistry (2005) 44, 2 242-250
a=14.7735(15)Å b=21.632(2)Å c=7.5450(7)Å
α=90° β=100.815(4)° γ=90°
C22H19N5O4Pt1S2
C22H19N5O4Pt1S2
Inorganic Chemistry (2005) 44, 2 242-250
a=14.7735(15)Å b=21.632(2)Å c=7.5450(7)Å
α=90° β=100.815(4)° γ=90°
2:1 Cholesterol:pentanol
2(C27H46O),C5H12O
Crystal Growth & Design (2012) 12, 1 231
a=42.9792(15)Å b=10.3021(4)Å c=6.2807(2)Å
α=90.00° β=96.225(2)° γ=90.00°
2:1 Cholesterol:Butanol solvate
2(C27H46O),C4H10O
Crystal Growth & Design (2012) 12, 1 231
a=15.0634(9)Å b=6.0931(4)Å c=29.1765(18)Å
α=90.00° β=96.583(3)° γ=90.00°
1:1 Cholesterol:Phenol solvate
C27H46O,C6H6O
Crystal Growth & Design (2012) 12, 1 231
a=11.5935(9)Å b=6.1697(5)Å c=21.1002(16)Å
α=90.00° β=105.446(4)° γ=90.00°
2:1 Cholesterol:hexanol solvate
2(C27H46O),C6H14O
Crystal Growth & Design (2012) 12, 1 231
a=42.982(2)Å b=10.3695(7)Å c=6.2684(4)Å
α=90.00° β=96.166(3)° γ=90.00°
1:1 Cholesterol:phenylethanol solvate
2(C27H46O),C8H10O
Crystal Growth & Design (2012) 12, 1 231
a=42.676(4)Å b=10.2044(11)Å c=6.3396(6)Å
α=90.00° β=97.501(6)° γ=90.00°
Olanzapine
C17H20N4S1
Crystal Growth & Design (2013) 13, 4 1602
a=10.3411(13)Å b=14.521(2)Å c=10.5314(14)Å
α=90.00° β=100.291(4)° γ=90.00°
Olanzapine
C17H20N4S1
Crystal Growth & Design (2013) 13, 4 1602
a=9.8544(14)Å b=16.314(2)Å c=9.9754(12)Å
α=90.00° β=98.304(8)° γ=90.00°
Olanzapine 2-butoxyethanol
C17H20N4S1,(C6H14O2)
Crystal Growth & Design (2013) 13, 4 1602
a=10.4420(10)Å b=17.7328(15)Å c=15.5165(13)Å
α=90.00° β=126.279(5)° γ=90.00°
Olanzapine 2,2,2-trifluoroethanol
C17H20N4S1,2(C2F3O1H3)
Crystal Growth & Design (2013) 13, 4 1602
a=12.7244(9)Å b=11.7538(8)Å c=16.0067(11)Å
α=90.00° β=94.782(2)° γ=90.00°
Olanzapine acetic acid
C17H20N4S1(C2O2H4)
Crystal Growth & Design (2013) 13, 4 1602
a=10.0427(11)Å b=12.7430(13)Å c=14.3886(15)Å
α=90.00° β=92.436(4)° γ=90.00°
Olanzapine ethyleneglycol
C17H20N4S1,(C2H6O2)
Crystal Growth & Design (2013) 13, 4 1602
a=9.8393(16)Å b=13.278(2)Å c=14.588(2)Å
α=90.00° β=96.328(7)° γ=90.00°
Olanzapine ethanol
C17H20N4S1,C2H6O1
Crystal Growth & Design (2013) 13, 4 1602
a=10.3489(18)Å b=13.003(2)Å c=13.870(2)Å
α=90.00° β=92.496(6)° γ=90.00°
Olanzapine TBMe hydrate
C17H20N4S1,(C5H12O1),2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.2070(1)Å b=12.2211(9)Å c=14.550(1)Å
α=90.00° β=109.239(3)° γ=90.00°
Olanzapine t-butanol hydrate
2(C17H20N4S1),2(C4H10O1),5(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.2491(9)Å b=12.3838(8)Å c=27.1418(17)Å
α=90.00° β=99.052(2)° γ=90.00°
Olanzapine 3-methyl 1-butanol hydrate
2(C17H20N4S1),2(C5H12O1),2(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=12.3420(17)Å b=13.3559(18)Å c=14.630(2)Å
α=105.883(6)° β=90.290(6)° γ=92.005(6)°
Olanzapine N,N dimethylforamide hydrate
2(C17H20N4S),(C3H7NO1)2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.9885(9)Å b=12.7558(7)Å c=19.8567(12)Å
α=90.00° β=93.348(2)° γ=90.00°
Olanzapine 1.4-butanediol hydrate
2(C17H20N4S1),(C4O2H10),2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=12.2637(11)Å b=14.1146(10)Å c=14.1783(12)Å
α=63.985(3)° β=65.649(4)° γ=65.437(4)°
Olanzapine-2-pentanol hydrate
C17H20N4S1,C5H12O1,H2O
Crystal Growth & Design (2013) 13, 4 1602
a=13.4466(10)Å b=12.3833(9)Å c=14.5522(9)Å
α=90.00° β=104.839(2)° γ=90.00°
Olanzapine N,N,N-triethylamine hydrate
(C17H20N4S),0.5(C6H15N)2(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=14.8170(10)Å b=12.6230(10)Å c=14.4610(10)Å
α=90.00° β=113.36(2)° γ=90.00°
Olanzapine pyridine hydrate
2(C17H20N4S1),(C5H5N)2(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=14.8824(7)Å b=12.7289(7)Å c=20.3218(11)Å
α=90.00° β=93.465(2)° γ=90.00°
Olanzapine 1-butanol hydrate
C17H20N4S1,0.5(C4H10O1),H2O1
Crystal Growth & Design (2013) 13, 4 1602
a=24.575(6)Å b=12.429(3)Å c=15.006(3)Å
α=90.00° β=125.255(7)° γ=90.00°
Olanzapine nitromethane hydrate
C17H20N4S1,0.5(CH3NO2),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.352(3)Å b=12.3706(13)Å c=15.0182(18)Å
α=90.00° β=125.531(5)° γ=90.00°
Olanzapine 1,2-dimethoxyethane hydrate
(C17H20N4s1),0.5(C4H10O2),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.4675(13)Å b=12.2298(8)Å c=15.1073(8)Å
α=90.00° β=125.675(2)° γ=90.00°
Olanzapine methanol
C17H20N4S1(C1H4O1)
Crystal Growth & Design (2013) 13, 4 1602
a=10.1493(9)Å b=12.2895(10)Å c=14.0944(13)Å
α=90.00° β=91.905(5)° γ=90.00°
Olanzapine dihydrate
C17H20N4S1,2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=9.846(2)Å b=12.672(3)Å c=14.384(3)Å
α=90.00° β=92.724(9)° γ=90.00°
Olanzapine dichloromethane
2(C17H20N4S1),1(CH2Cl2)
Crystal Growth & Design (2013) 13, 4 1602
a=9.6671(15)Å b=11.5070(17)Å c=16.697(2)Å
α=103.991(6)° β=96.989(6)° γ=99.825(6)°
Olanzapine 1,4-dioxan hydrate
C17H20N4S,0.5(C4H8O2),(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=24.447(3)Å b=12.5660(16)Å c=14.9591(19)Å
α=90.00° β=125.421(5)° γ=90.00°
Olanzapine acetonitrile hydrate
(C17H20N4S1),(C2H3N1),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.381(2)Å b=12.3856(9)Å c=15.0565(14)Å
α=90.00° β=125.321(7)° γ=90.00°
Olanzpaine tetrahydrofuran hydrate
C17H20N4S,0.5(C4H8O),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.2355(10)Å b=12.5913(5)Å c=15.0767(6)Å
α=90.00° β=124.9990(10)° γ=90.00°
Olanzapine acetone hydrate
C17H20N4S1,0.5(C3O1H6),(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=24.226(2)Å b=12.5269(12)Å c=15.0737(15)Å
α=90.00° β=124.976(4)° γ=90.00°
Olanzapine methylacetate hydrate
C17H20N4S1,0.5(C3H6O2),H2O1
Crystal Growth & Design (2013) 13, 4 1602
a=24.899(4)Å b=12.5316(19)Å c=15.243(2)Å
α=90.00° β=126.990(5)° γ=90.00°
Olanzapine 1,2 propanediol hydrate
C17H20N4S1,(C3H8O2),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.704(2)Å b=12.1883(10)Å c=15.1242(12)Å
α=90.00° β=125.206(3)° γ=90.00°
Olanzapine 1-propanol hydrate
C17H20N4S1,0.5(C3H8O1),(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=24.4748(13)Å b=12.3515(6)Å c=15.1109(8)Å
α=90.00° β=125.6490(10)° γ=90.00°
Olanzapine higher hydrate
C17H20N4S1,2.5(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=24.940(6)Å b=12.156(3)Å c=14.867(3)Å
α=90.00° β=124.928(6)° γ=90.00°
Quinol:2Piperidine
2(C5H11N)(C6H6O2)
Acta Crystallographica Section B (2005) 61, 1 46-57
a=10.4230(15)Å b=5.2619(7)Å c=15.221(2)Å
α=90.00° β=109.920(3)° γ=90.00°
Paracetamol hemi-piperazine
2[C8H9NO2][C4H10N2]
Acta Crystallographica Section B (2002) 58, 6 1057-1066
a=15.893(5)Å b=5.1664(17)Å c=12.993(4)Å
α=90.00° β=113.633(5)° γ=90.00°
TGF beta
C22H19N5O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.2599(3)Å b=19.6072(14)Å c=12.6913(6)Å
α=90° β=116.545(2)° γ=90°
TGF Beta
C26H29N5O2
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.1145(8)Å b=12.0611(13)Å c=12.5401(13)Å
α=88.454(5)° β=79.842(4)° γ=76.813(5)°
TGF beta
C22H19N5O,C4H9NO
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=8.6946(4)Å b=10.9640(4)Å c=12.9344(5)Å
α=77.7370(16)° β=88.5612(17)° γ=79.1558(19)°
C22H19N5O,C4H8O
C22H19N5O,C4H8O
Journal of the American Chemical Society (2019) 141, 35 13887-13897
a=9.8533(7)Å b=11.2079(6)Å c=11.5743(6)Å
α=101.869(2)° β=105.813(2)° γ=105.560(2)°
2:1 Cholesterol:Propanol solvate
2(C27H46O),C3H8O
Crystal Growth & Design (2012) 12, 1 231
a=15.0249(12)Å b=6.1107(5)Å c=28.663(2)Å
α=90.00° β=97.386(4)° γ=90.00°
2:1:1 Cholesterol: Benzyl alcohol hydrate
2(C27H48O),C7H8O,H2O
Crystal Growth & Design (2012) 12, 1 231
a=15.699(2)Å b=7.5133(9)Å c=23.492(3)Å
α=90.00° β=94.643(9)° γ=90.00°